Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by qwerty22on Nov 14, 2022 5:41pm
112 Views
Post# 35098102

RE:RE:RE:RE:RE:RE:13 G filing

RE:RE:RE:RE:RE:RE:13 G filing

"The shares of common stock reported in this row are held by Soleus Capital Master Fund, L.P. (“Master Fund”), and include a presently exercisable warrant to purchase up to 1,550,000 shares of common stock at an exercise price of $3.14 per share (the “Warrant”). Soleus Capital, LLC is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. "

So for people that don't understand these types of transactions, like me, why would Soleus do this?


palinc2000 wrote:

https://www.theratech.com/static-files/446de95b-5b8e-4464-9058-dd6bbd822fc7

 

SPCEO1 wrote: I cannot find that filing - where did you see it? Is it from today?
 

 

palinc2000 wrote:

 

My understsnfing is that the Filing is simply to account for the transfer of the shsres ftom Soleus to a General Partner controlled by Soleus

palinc2000 wrote: [The 9.5 mil'ion includes 1555000 warrabts 

quote=palinc2000]

 

Seems like Soleus hold 9.5 million shares representing 10.1 %

 

palinc2000 wrote: Soleus

 

 


 

 




[/quote]

<< Previous
Bullboard Posts
Next >>